Toprol-XL patents found invalid
Executive Summary
The U.S. Court of Appeals for the Federal Circuit upheld a district court ruling that AstraZeneca's Toprol-XL (metoprolol succinate) patents are invalid and unenforceable based on double patenting. However, the court vacated the lower court's finding of inequitable conduct by AstraZeneca. The court concluded that there are questions of fact involving AstraZeneca's failure to disclose a dispute over inventorship to the U.S. Patent and Trademark Office and sent the issue back to the U.S. District Court for the Eastern District of Missouri for review. AstraZeneca filed suit against KV Pharmaceutical, Andrx and Eon Labs after they filed ANDAs to market generic versions of the hypertension treatment. Sandoz and KV subsequently filed citizen petitions to block each other from marketing formulations of the drug (1"The Pink Sheet" July 9, 2007, p. 26)...
You may also be interested in...
Generic Firms Use Pediatric Exclusivity As Weapon In Toprol XL Fight
Sandoz and KV Pharmaceutical are locked in a regulatory struggle to keep each other's generic versions of AstraZeneca's Toprol XL (metoprolol extended release) off the market
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.